

Fungal Infections Could Be Linked to Genetic Mutations

BY MARY ANN MOON

Genetic mutations that impair dectin-1 function have been tied to susceptibility to fungal infection in two families, according to two separate reports.

In the first study, genetic assessments were performed in a large, consanguineous Iranian family to determine whether a mutated gene was responsible for their nonsyndromic fungal infections, noted Dr. Erik-Oliver Glocker of Royal Free Hospital and University College London and his associates.

The index patient was a 19-year-old man who had had oral candidiasis since the age of 3 years but was otherwise healthy. This patient had a brother with intermittent thrush throughout his childhood and adolescence, and then suddenly died at age 19 of meningitis that proved to be caused by *Candida* species.

The mother of both boys, aged 50 at the time of the study, had had vaginal candidiasis since age 42. Her adult sister also had had oral and vaginal candidiasis since childhood, and their brother had had dermatophytosis since childhood. Both of this man's daughters, who both died suddenly at age 15, were given post-mortem diagnoses of invasive candidal meningoencephalitis. Blood samples were obtained for DNA analysis from 36 family members and were compared with those from 50 healthy Iranian blood donors and 180 healthy white donors of other nationalities.

A previously unknown mutation in the CARD9 gene was found in 4 affected patients and 18 other relatives, but not in any of the control samples. The CARD9 gene "plays a central role in antifungal defense by receiving signals from several antifungal pattern-recognition receptors and stimulating proinflammatory responses," the investigators noted.

"Our study shows that a homozygous point mutation in CARD9 ... is associated with a susceptibility to fungal infections," Dr. Glocker and his colleagues wrote. The mutation impairs the function of dectin-1, a transmembrane pattern-recognition receptor that senses the beta-glucan component of fungal cell walls (N. Engl. J. Med. 2009;361:1727-35).

In the second study, genetic analyses were performed on mononuclear cells from a patient with recurrent vulvovaginal and oral or esophageal candidiasis, as well as on cells from four relatives. The patient's two sisters had chronic onychomycosis; one of them also had recurrent vulvovaginal candidiasis. Their mother had chronic onychomycosis, and their father had transient onychomycosis.

The index patient had been found to have defective cytokine production in response to stimulation with *C. albicans* and with beta-glucan, indicating a potential defect in dectin-1 recognition, according to Bart Ferwerda, Ph.D., of Radboud University, Nijmegen, the Netherlands, and his associates.

The researchers identified a homozygous mutation that caused defective surface expression of dectin-1. This apparently caused an impaired cytokine response by monocytes and macrophages but did not affect the normal killing of *C. albicans* by neutrophils (N. Engl. J. Med. 2009;361:1760-7). Neither Dr. Glocker nor Dr. Ferwerda reported any financial conflicts of interest. ■



Fungal infections, such as onychomycosis, have been traced back to genetic mutations found in families.

Multiple mechanisms of action of AZA¹

Continuous improvement in lesions and erythema^{2,3}

36-week maintenance data⁴

Additional patient benefits*

For the multi-faceted challenges of mild to moderate rosacea

offering more
could work
wonders

Finacea[®]
(azelaic acid) Gel, 15%

***myfinaceaskinsavvy.com** – a website for patient support and education

Finacea is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.

Finacea is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. Finacea is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety—Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexion, these patients should be monitored for early signs of hypopigmentation.

Please see brief summary of full Prescribing Information on following page.

References: 1. Draelos ZD, Kayne AL. Implications of azelaic acid's multiple mechanisms of action: therapeutic versatility. Poster presented at: 66th Annual Meeting of the American Academy of Dermatology; February 1-5, 2008, San Antonio, TX. 2. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. *J Am Acad Dermatol.* 2003;48(6):836-845. FINACEA was only studied in clinical trials for 12 weeks. 3. Elewski BE, Fleischer AB, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. *Arch Dermatol.* 2003;139:1444-1450. 4. Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. *J Drugs Dermatol.* 2009;8(7):639-648.

©2009 Intendis, Inc. All rights reserved. 09-JA-004 October 2009